Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-01-21
1996-04-09
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514284, 514647, 514661, 514662, A61K 3144, A61K 31135, A61K 3113
Patent
active
055062318
ABSTRACT:
Damage to CNS neurons of a human patient infected with a human immunodeficiency virus is reduced by administering an antagonist of the NMDA receptor complex.
REFERENCES:
patent: 3328251 (1967-06-01), Smith
patent: 3391142 (1968-07-01), Mills et al.
patent: 3456057 (1969-07-01), Cairns et al.
patent: 4122193 (1978-10-01), Scherm et al.
patent: 4148896 (1979-04-01), Smith et al.
patent: 4273774 (1981-06-01), Scherm
patent: 4351847 (1982-09-01), Griffith et al.
patent: 4806543 (1989-02-01), Choi
patent: 4812458 (1989-03-01), Honore et al.
patent: 4837218 (1989-06-01), Olney
patent: 5053419 (1991-10-01), Lipton
patent: 5061703 (1991-10-01), Bormann et al.
Merk Index 10th Ed. No. A7, 1983.
Merk Index 10th Ed. No. 8116, 1983.
Merk Index 10th Ed. No. 373, 1983.
Choi et al., J. Pharm. and Exp. Therapeutics 242:713-720 (1987).
Pomerantz et al., New Eng. Med. 317:1643-1647 (1987).
Brenneman et al., Nature 335:639-642 (1988).
Price et al., Science 239:586-590 (1988).
Davenport et al., Eur. J. Pharm. 154:73-78 (1988).
Goldenberg et al., J. Pharm. and Exp. Therapeutics 245:1081-1087 (1988).
Hahn et al., Proc. Nat'l. Acad. Sci. USA 85:6556-6560 (1988).
Ho et al., Annals of Internal Med. 111:400-410 (1989).
Turski et al., Nature 349:414-418 (1989).
Kornhuber et al., European J. Pharm. 166:589-590 (1989).
Borman, European J. Pharm. 166:591-592 (1989).
Aizenman et al., Neuron 2:1257-1263 (1989).
Sernagor et al., Neuron 2:1221-1227 (1989).
Seubert et al., Brain Research 492:366-370 (1989).
Turski Arzneim-Forsch./Drug Res. 40 (I) Nr. 5 (1990).
Muller SCRIP 1515 p. 28 (1990).
Asanaka et al. 112 Chem. Abstract 232458q (1990).
Krieglstein et al., 112 Chem. Abstract 112: 522c (1990).
Nuglisch et al., 113 Chem. Abstract 113: 224453q (1990).
Lipton et al., Neurosci. Abstracts 18:757, No. 321.11, 1992.
Lipton et al. Trends in Neurosci. 15:75-79 (1992).
Lipton et al. Nature 367:113-114 (1994).
Dreyer et al., "HIV-1 Coat Protein Neurotoxicity Prevented by Calcium Channel Antagonists", Science 248:364-367, Apr. 20, 1990.
Lipton et al., Neuron, vol. 7: 111-118, 1991.
Lo et al., Brain Research, "HIV-1 envelope protein evokes intracellular calcium oscillations in rat hippocampal neurons", Brain Research, 594:189-196 (1992).
Perovic et al., "The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-Methyl-D-aspartate and gp 120 of HIV-1", Eur. J. of Pharmacol., 228:27-33 (1994).
Muller et al., "gp 120 of HIV-1 induces apoptosid in rat cortical cell cultures: prevention by memantine", Eur. J. of Pharmac., 226:209-214 (1992).
Giulian et al., "The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes", Proc. Natl. Acad. Sci. USA, 90:2769-2773 (1993).
Rytik et al., "Susceptibility of Primary Human Glial Fibrillary Acidic Protein-Positive Brain Cells to Human Immunodeficiency Virus Infection In Vitro . . . ", Aids Res. and Human Retroviruses 7:89-95 (1991).
Brightbart et al., The Lancet 2(8626):1488-1489 (1988).
Meldrum et al., "Excitatory amino acid neurotoxicity and neurodegenerative disease", Trends in Pharmac. Sciences, 11:379-387 (1990).
Cintins Marianne M.
Jarvis William R. A.
The Children's Medical Center Corporation
LandOfFree
Treatment of aids dementia, myelopathy and blindness does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of aids dementia, myelopathy and blindness, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of aids dementia, myelopathy and blindness will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-139200